Novo Nordisk CEO to face Senate questions amid pricing controversy
Novo Nordisk is under pressure over US drug prices as CEO Lars Fruergaard Jørgensen prepares to testify before the Senate HELP committee. The focus will be on high costs of Wegovy and Ozempic, with Senator Bernie Sanders criticizing the prices.
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company executive.
Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...
It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
As Novo Nordisk rakes in billions, Sen. Bernie Sanders and public health advocates demand answers on why U.S. patients are charged sky-high prices for life-saving drugs like Ozempic while generics ...
The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...
Health-care companies fell amid fears of pharmaceutical drug-price controls. Novo Nordisk's Ozempic is "very likely" to be one the next drugs to have its price slashed in bargaining with the U.S.
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Investors including Quadria Capital and Denmark-based pharmaceutical major Novo Nordisk are among those interested in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback